New study breakthrough by Human Data Sciences in the field of comparative outcomes research
Human Data Sciences (HDS), a leading provider of data and research services for the life science industry, has announced an update to its real-world data analytics platform, Livingstone. This innovative update focuses on comparative outcomes studies, a first in the sector to offer fully automated multi-endpoint comparisons for use in regulatory and Health Economics and Outcomes Research (HEOR) contexts.
The Livingstone platform automates the entire process of comparative outcomes studies, applying standardised risk adjustment, longitudinal tracking, and validated real-world endpoints across all outcomes of interest. It draws on high-quality real-world data, including anonymised UK patient records from the Clinical Practice Research Datalink (CPRD).
One of the key advantages of the Livingstone platform is its ability to compare disease trajectories and intervention outcomes across defined cohorts and timeframes. This capability allows researchers to conduct comparative outcomes studies across multiple endpoints simultaneously, offering a radically improved evidence base for HEOR professionals and regulators.
The update also enables researchers to perform feasibility assessments, burden of illness and epidemiological profiling, and resource utilisation and cost-of-care studies. The platform's ability to generate regulator-ready outputs has already proven valuable for teams navigating diverse jurisdictional requirements.
Key features of the Livingstone platform include comparative outcomes analysis, integration with electronic health records (EHRs) and real-time data, predictive modeling and clinical AI, and automated, intelligent clinical decision support. These features aim to improve patient outcomes, accelerate research and drug development, enhance data utilisation, and operational efficiency in the life sciences industry.
Early adopters of Livingstone include major pharmaceutical manufacturers using the platform for early market access planning, global Health Technology Assessment (HTA) submissions, and comparative safety evaluations in various regions.
By leveraging advanced data analytics and AI, the Livingstone platform delivers real-time, actionable insights that support clinical and research decisions, ultimately enhancing care quality and innovation in life sciences.
[1] AI-Powered Clinical Platforms: A New Era in Healthcare ([link](https://www.forbes.com/sites/forbestechcouncil/2021/07/28/ai-powered-clinical-platforms-a-new-era-in-healthcare/?sh=7b73a5645428)) [2] The Impact of AI on Healthcare: A Comprehensive Review ([link](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003437/)) [3] The Role of AI in Personalised Medicine ([link](https://www.nature.com/articles/s41598-018-22457-9))
The Livingstone platform, integrating science, technology, and digital health, is becoming a valuable tool in the life sciences industry. It automates comparative outcomes studies, aiding in medical-conditions research and the development of health-and-wellness strategies that rely on real-world data and AI-powered predictive modeling.
